A multicenter, retrospective study, presented at the European Academy of Allergy and Clinical Immunology Congress 2017, suggests that the benefit of omalizumab is greater in patients who have early-onset allergic asthma or severe asthma with frequent exacerbations as compared to those who have other asthma phenotypes.